Chemoinformaics analysis of NOROXYHYDRASTININE
| Molecular Weight | 191.186 | nRot | 0 |
| Heavy Atom Molecular Weight | 182.114 | nRig | 16 |
| Exact Molecular Weight | 191.058 | nRing | 3 |
| Solubility: LogS | -2.605 | nHRing | 2 |
| Solubility: LogP | 1.141 | No. of Aliphatic Rings | 2 |
| Acid Count | 0 | No. of Aromatic Rings | 1 |
| Base Count | 0 | No. of Aliphatic Carbocycles Rings | 0 |
| Atoms Count | 23 | No. of Aliphatic Hetero Cycles | 2 |
| No. of Heavy Atom | 14 | No. of Aromatic Carbocycles | 1 |
| nHetero | 4 | No. of Aromatic Hetero Cycles | 0 |
| nBridge Head | 0 | No. Saturated Carbocycles | 0 |
| No. of Hydrogen atom | 9 | No. of Saturated Hetero Cycles | 0 |
| No. of Carbon atom | 10 | No. of Saturated Rings | 0 |
| No. of Nitrogen atom | 1 | No. of Arom Atom | 6 |
| No. of Oxygen atom | 3 | No. of Arom Bond | 6 |
| nHA | 3 | APOL | 26.2071 |
| nHD | 1 | BPOL | 13.9389 |
| QED | 0.656 |
| Synth | 2.377 |
| Natural Product Likeliness | 0.865 |
| NR-PPAR-gamma | 0.004 |
| Lipinski | Accepted |
| Pfizer | Accepted |
| GSK | Accepted |
| Golden Triangle | Rejected |
| Pgp-inh | 0.002 |
| Pgp-sub | 0.101 |
| HIA | 0.002 |
| CACO-2 | -4.653 |
| MDCK | 0.0000155 |
| BBB | 0.671 |
| PPB | 0.697352 |
| VDSS | 1.697 |
| FU | 0.277126 |
| CYP1A2-inh | 0.984 |
| CYP1A2-sub | 0.385 |
| CYP2c19-inh | 0.667 |
| CYP2c19-sub | 0.36 |
| CYP2c9-inh | 0.114 |
| CYP2c9-sub | 0.674 |
| CYP2d6-inh | 0.895 |
| CYP2d6-sub | 0.435 |
| CYP3a4-inh | 0.63 |
| CYP3a4-sub | 0.17 |
| CL | 10.214 |
| T12 | 0.601 |
| hERG | 0.022 |
| Ames | 0.548 |
| ROA | 0.033 |
| SkinSen | 0.175 |
| Carcinogencity | 0.925 |
| EI | 0.064 |
| Respiratory | 0.041 |
| NR-Aromatase | 0.027 |
| Antiviral | No |
| Prediction | 0.871655 |